Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Comprehensive characterization of drug-response, genome, and drug-responsive transcriptome in gastric cancer cell lines

PROVIDER: PRJDB10743 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	DRR255089.fastq.gz	Fastqsanger.gz
	DRR255090.fastq.gz	Fastqsanger.gz
	DRR255091.fastq.gz	Fastqsanger.gz
	DRR255092.fastq.gz	Fastqsanger.gz
	DRR255093.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

mRNA expression profiles of newly established 49 gastric cancer cell lines.

Project description:Establishment and molecular characterization of 49 peritoneally-metastatic gastric cancer cell lines from 18 patients’ ascites. We performed comprehensive transcriptome analyses using microarrays of our established gastric cancer cell lines.

2023-04-01 | GSE172197 | GEO

mRNA expression profiles of 7 gastric cancer cell lines and primary cancer cells.

Project description:Molecular characterization of 7 peritoneally-metastatic gastric cancer cell lines and primary cancer cells established from a patients’ ascites. We performed comprehensive transcriptome analyses using microarrays of our established gastric cancer cell lines and primary cancer cells.

2023-04-01 | GSE172196 | GEO

Homo sapiens

Project description:Gastric Cancer Cell Lines

| PRJNA107785 | ENA

Homo sapiens

Project description:Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines

| PRJNA93615 | ENA

Homo sapiens

Project description:Multi-omics characterization of drug perturbations in lung cancer cell lines

| PRJDB6952 | ENA

Pembrolizumab in metastatic gastric cancer

Project description:Pembrolizumab in metastatic gastric cancer: comprehensive molecular characterization of clinical response

| PRJEB25780 | ENA

Effect of zebularine on primary human liver cancer cell lines

Project description:Transcriptomic changes in human liver cancer cell lines caused by the demethylating drug zebularine. Epigenomic changes such as aberrant hypermethylation and subsequent atypical gene silencing are characteristic features of human cancer. Here, we report a comprehensive characterization of epigenomic modulation caused by zebularine, an effective DNA methylation inhibitor, in human liver cancer. Using transcriptomic and epigenomic profiling, we identified a zebularine signature that classified liver cancer cell lines into two major subtypes with different drug-responses. In drug-sensitive cell lines, zebularine caused inhibition of proliferation coupled with increased apoptosis, whereas drug-resistant cell lines were associated with upregulation of oncogenic networks (e.g. E2F1, MYC, and TNF) driving liver cancer growth in vitro and in mice. Assessment of zebularine-based therapy in xenograft mouse models demonstrated potent therapeutic effects against tumors established from zebularine-sensitive but not zebularine-resistant liver cancer cells leading to increased survival and decreased pulmonary metastasis. Integration of zebularine gene expression and demethylation response signatures differentiated patients with HCC according to their survival and disease recurrence and identified a subclass of patients within the poor survivors likely to benefit from therapeutic agents that target the cancer epigenome. Each cell line was mock treated or treated with 100uM and 200uM zebularine for 7 days, respectively *** This Series represents the gene expression component of the study.

2011-07-30 | E-GEOD-23991 | biostudies-arrayexpress

Homo sapiens

Project description:Epigenetic analysis of gastric cancer cell lines

| PRJNA141379 | ENA

Homo sapiens

Project description:MET Amplified Gastric Cancer Cell Lines +/- Crizotinib

| PRJNA310017 | ENA

Homo sapiens

Project description:Genotypic and phenotypic characterization of the side population of gastric cancer cell lines

| PRJNA124329 | ENA